Sales of Pfizer’s COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61%. https://t.co/04Nh6T78w7
— ABC News (@ABC) May 4, 2022
There are only three COVID-19 vaccines authorized for use in the United States. 217 million doses of Moderna’s shot and 341 million doses of Pfizer’s have been administered in the United States since the shots were approved nearly a year and a half ago, according to the Centers for Disease Control and Prevention (CDC). The third available shot, from Johnson & Johnson, has been administered just 18.7 million times.
Moderna soared well beyond Wall Street expectations for the quarter, reporting a profit of $8.58 per share compared to analyst predictions of $5.18 per share, according to the Associated Press. Pfizer also exceeded expectations, with earnings of $1.62 per share compared to predictions of $1.49 per share.